Search Results for: FGFR3

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel GMPS guanine monophosphate synthase
  • Purine ribonucleoside monophosphate biosynthesis
  • Glutamic acid
Novel ADD1 adducin 1
  • Caspase-mediated cleavage of cytoskeletal proteins
  • XBP1(S) activates chaperone genes
  • Miscellaneous transport and binding events
Novel GRK4 G protein-coupled receptor kinase 4
Novel IDUA alpha-L-iduronidase
  • HS-GAG degradation
  • CS/DS degradation
  • MPS I - Hurler syndrome
  • Mucopolysaccharidosis type I (MPS1); Hurler-Scheie syndrome (MPS1HS); Hurler syndrome (MPS1H); Scheie syndrome (MPS1S)
Novel IRF2BPL interferon regulatory factor 2 binding protein like
Novel STK32B serine/threonine kinase 32B
CTSK cathepsin K
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Trafficking and processing of endosomal TLR
  • MHC class II antigen presentation
  • RUNX1 regulates transcription of genes involved in differentiation of keratinocytes
  • [1-(4-Fluorobenzyl)Cyclobutyl]Methyl (1s)-1-[Oxo(1h-Pyrazol-5-Ylamino)Acetyl]Pentylcarbamate
  • Cyanamide
  • 3-amino-5-phenylpentane
  • N2-[(Benzyloxy)carbonyl]-N-[(3R)-1-{N-[(benzyloxy)carbonyl]-L-leucyl}-4-oxo-3-pyrrolidinyl]-L-leucinamide
  • N2-[(benzyloxy)carbonyl]-n1-[(3S)-1-cyanopyrrolidin-3-yl]-l-leucinamide
  • N-[(2S)-4-Methyl-1-oxo-1-{[(4S)-3-oxo-1-(2-pyridinylsulfonyl)-4-azepanyl]amino}-2-pentanyl]-1-benzofuran-2-carboxamide
  • Dibenzyl (carbonylbis{2,1-hydrazinediyl[(2S)-4-methyl-1-oxo-1,2-pentanediyl]})biscarbamate
  • N2-({[(4-Bromophenyl)Methyl]Oxy}Carbonyl)-N1-[(1s)-1-Formylpentyl]-L-Leucinamide
  • (2R)-2-(3-Biphenylyl)-N-{(2R)-2-hydroxy-3-[(2-pyridinylsulfonyl)amino]propyl}-4-methylpentanamide
  • Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate
  • MIV-701
  • Relacatib
  • Odanacatib
  • 1-{7-cyclohexyl-6-[4-(4-methylpiperazin-1-yl)benzyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}methanamine
  • (2R)-3-Methyl-1-phenyl-2-butanyl [(2S)-1-oxo-2-hexanyl]carbamate
  • 1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE
  • 6-(cyclohexylamino)-9-[2-(4-methylpiperazin-1-yl)-ethyl]-9H-purine-2-carbonitrile
  • 9-CYCLOPENTYL-6-[2-(3-IMIDAZOL-1-YL-PROPOXY)-PHENYLAMINO]-9H-PURINE-2-CARBONITRILE
  • N-(2-AMINOETHYL)-N~2~-{(1S)-1-[4'-(AMINOSULFONYL)BIPHENYL-4-YL]-2,2,2-TRIFLUOROETHYL}-L-LEUCINAMIDE
  • (1R,2R)-N-(2-Aminoethyl)-2-{[(4-methoxyphenyl)sulfonyl]methyl}cyclohexanecarboxamide
  • TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE
  • MIV-711
  • Pycnodysostosis
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
FGF1 fibroblast growth factor 1
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR1b ligand binding and activation
  • FGFR3b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR2b ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR2 IIIa TM
  • Signaling by FGFR3 point mutants in cancer
  • Pentosan polysulfate
  • Amlexanox
  • Heparin
  • Sucrosofate
  • Formic acid
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • Naphthalene Trisulfonate
  • Pazopanib
  • 5-aminonaphthalene-2-sulfonic acid
  • Foreskin fibroblast (neonatal)
  • Foreskin keratinocyte (neonatal)
FGF2 fibroblast growth factor 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR1b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR2b ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Syndecan interactions
  • Non-integrin membrane-ECM interactions
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR2 IIIa TM
  • Signaling by FGFR3 point mutants in cancer
  • Sucralfate
  • Pentosan polysulfate
  • Sirolimus
  • Heparin
  • 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
  • ABT-510
PTK2B protein tyrosine kinase 2 beta
  • Signal regulatory protein family interactions
  • VEGFA-VEGFR2 Pathway
  • Interleukin-2 signaling
  • Leflunomide
  • Genistein
  • 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide
  • Baricitinib
  • Fostamatinib
FGF4 fibroblast growth factor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 point mutants in cancer
  • Pentosan polysulfate
  • Heparin
  • TP-508
KRT8 keratin 8
  • Keratinization
  • Formation of the cornified envelope
  • Tenecteplase
  • Lanoteplase
  • Copper
RPL8 ribosomal protein L8
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Peptide chain elongation
  • SRP-dependent cotranslational protein targeting to membrane
  • SRP-dependent cotranslational protein targeting to membrane
  • Viral mRNA Translation
  • Selenocysteine synthesis
  • Major pathway of rRNA processing in the nucleolus and cytosol
  • Formation of a pool of free 40S subunits
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Termination
  • Regulation of expression of SLITs and ROBOs
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • (S)-3-phenyllactic acid
  • Anisomycin
  • Puromycin
SRPK2 SRSF protein kinase 2
  • Adenine
  • Purvalanol
  • Phosphoaminophosphonic Acid-Adenylate Ester
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
RPS6KA3 ribosomal protein S6 kinase A3
  • ERK/MAPK targets
  • CREB phosphorylation
  • Senescence-Associated Secretory Phenotype (SASP)
  • Senescence-Associated Secretory Phenotype (SASP)
  • Recycling pathway of L1
  • CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling
  • RSK activation
  • RSK activation
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Acetylsalicylic acid
  • Fostamatinib
  • Non-syndromic X-linked mental retardation
  • Coffin-Lowry syndrome (CLS)
SLC25A6 solute carrier family 25 member 6
  • Mitochondrial protein import
  • Mitochondrial protein import
  • Influenza Virus Induced Apoptosis
  • Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization
  • Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane
  • Clodronic acid
  • Etidronic acid
ATF3 activating transcription factor 3
  • ATF4 activates genes in response to endoplasmic reticulum stress
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • Response of EIF2AK1 (HRI) to heme deficiency
  • Response of EIF2AK1 (HRI) to heme deficiency
  • Pseudoephedrine
EPHA4 EPH receptor A4
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Fostamatinib

Page 1 out of 3 pages